One missed rule can cost you your license.

You can buy once — no subscription required. The $49 State Compliance Snapshot is an instant, source-linked report of every published med-spa and injectable change for your state, with the federal record included; if you subscribe within 30 days, the $49 is credited toward it. The $99 Peptide & GLP-1 Status Pack adds what your state's law says about a compounded GLP-1 or peptide program — office use, sterile licensing, out-of-state suppliers and dispensing — and is sold only where we have confirmed at least three of those four answers from cited law (currently Alaska, California, Colorado, Connecticut, Florida, Georgia, Idaho, Iowa, Mississippi and Texas); its price is credited toward a subscription the same way, and the federal standings on their own stay free on /tracker. All-Access members get every pack included for their states. Monitoring, not legal advice.

It depends on two things that change frequently: whether the drug is on the FDA shortage list, and your state’s rules. Under federal law (sections 503A and 503B), a compounder generally may not make a copy of a commercially available drug — being on the FDA shortage list has been the main exception that allowed compounded semaglutide and tirzepatide. When the FDA declared those shortages resolved, the basis for compounded versions narrowed sharply. MedSpaRadar tracks FDA shortage status and state action daily so you know when it changes. This is regulatory monitoring, not legal advice.

A PCAC review tag or vote alone does not determine compounding eligibility. Assess the exact substance, form and route against the applicable monograph, approved-drug-component, final 503A Bulks List and FDA interim-policy provisions. Category 1 means a nomination under evaluation, not final-list inclusion or FDA approval. FDA’s January 2025 policy describes conditional enforcement discretion requiring manufacturer registration, a valid certificate of analysis and all other applicable 503A conditions; it does not apply to Category 2. FDA is not bound by PCAC recommendations. Advisory votes are nonbinding and the tracker does not certify their primary tallies. FDA intends a further meeting before the end of February 2027 for GHK-Cu, Melanotan II, LL-37, Dihexa acetate and PEG-MGF; the exact date is unannounced. Its May 14, 2026 nomination document lists GHK-Cu except injectable routes in Category 1, so route matters. The tracker links dated records and policy context; it does not establish current individual eligibility. This is regulatory monitoring, not legal advice.

The MedSpaRadar substance tracker lists every peptide and GLP-1 we monitor with its published federal record — 503A Bulks List status, PCAC review history, and any state overlay — each linked to the government document it came from and dated. Where an outcome has so far only been reported by trade press (as with the July 2026 PCAC votes), it is marked "reported" until FDA’s primary record posts, and primary vote-tally verification is not established here. Source-event dates and recent polls are not current eligibility verification dates. It is free to view. Monitoring, not legal advice.

The FDA drug shortage list is a primary factor in whether compounding pharmacies (503A) and outsourcing facilities (503B) may prepare copies of a drug such as semaglutide or tirzepatide. When a GLP-1 comes off the shortage list, that basis for compounding generally ends — often after a short wind-down period. We monitor the list and alert you as soon as a GLP-1’s status changes.

503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities make larger batches under tighter FDA oversight and cGMP standards. For GLP-1s, both pathways generally hinge on FDA shortage status. The distinction drives which compounded products a med spa can legally source and from whom — so a change to either pathway can affect your supply overnight.

In most states, yes. Aesthetic procedures like injectables and lasers are considered the practice of medicine, which typically requires a physician owner, a medical director, or a supervising/delegating physician relationship. The specifics — ownership rules, delegation, chart review, and how often the physician must be involved — vary by state and change through legislation, which is exactly what MedSpaRadar tracks.

A good-faith exam (GFE) is a clinical evaluation required before a patient is treated — for example before Botox or filler — to establish a valid provider-patient relationship and a treatment order. States increasingly regulate who may perform the GFE and whether it can be done over telehealth. New GFE rules are one of the most common scope-of-practice changes we surface.

It varies widely by state. Some states grant nurse practitioners broad independent authority; others require a delegating or supervising physician, an established good-faith exam, or physician availability. Because these scope-of-practice rules change through state legislation and licensing-board action, the safe answer is state-specific — and it moves. MedSpaRadar monitors all 50 states and DC for exactly these changes.

The practical challenge is awareness: rules change through hundreds of state bills plus FDA and Federal Register activity every session, and a single missed change can put a license or the business at risk. MedSpaRadar monitors all of those sources daily, scores each change for impact, and tells you in plain language what changed and what to do — so compliance starts with knowing first.

No, and that is deliberate. Monitoring is what we read; alerts are what we send, and the second is much smaller than the first. We monitor selected primary sources on the schedules listed at medsparadar.com/data-sources on top of the legislative and federal sweep, and store every item with the publisher's own payload and the time we first saw it. Most of what that catches is real, sourced, and irrelevant to a practice — single-shipment border records, routine facility citations, agency notices about other industries. A human reviews material alerts before publication. Capped background items from FDA Import Refusal and FDA Inspection Citation may auto-publish to the feed only; they cannot email. Every email-eligible item requires human approval, and publishing is itself a separate decision from emailing. A wider net means fewer things missed, not more things in your inbox.

Yes. There is a free, public tier that needs no subscription: peptide and GLP-1 substance standings, per-state coverage posture, and freshness metadata, documented at medsparadar.com/api. Any paid plan additionally includes API access to the cited rules corpus and the changes feed for the states that plan covers — you issue the key yourself from your dashboard, no sales call. That key is licensed for internal use: pointing your own dashboard, matter-management system, or a recurring internal check at it. Redistributing the corpus inside something you hand a third party — a client report, a portal, a product you sell — is a separate redistribution licence, scoped with us first. Every response carries its own attribution, including the LegiScan CC BY 4.0 line. Monitoring, not legal advice.

Med-spa owners, injectors, nurse practitioners, medical directors, and practice managers — anyone who offers GLP-1 weight-loss programs, injectables, or other aesthetic services and cannot afford to miss a scope-of-practice or compounding change that affects their license or their business.